Apolone, G.; Ardizzoni, A.; Biondi, A.; Bortolami, A.; Cardone, C.; Ciniselli, C.M.; Conte, P.; Crippa, C.; de Braud, F.; Duca, M.; Gori, S.; Gritti, G.; Inno, A.; Luksch, R.; Lussana, F.; Maio, M.; Pasello, G.; Perrone, F.; Rambaldi, A.; Rossi, G.; Signorelli, D.; Soverini, G.; Valente, M.; Verderio, P.; Buzzetti, G., Skip pattern approach toward the early access of innovative anticancer drugs, «ESMO OPEN», 2021, 6, Article number: 100227, pp. 1 - 8 [articolo]Open Access
Dingemans A.-M.C.; Fruh M.; Ardizzoni A.; Besse B.; Faivre-Finn C.; Hendriks L.E.; Lantuejoul S.; Peters S.; Reguart N.; Rudin C.M.; De Ruysscher D.; Van Schil P.E.; Vansteenkiste J.; Reck M., Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆, «ANNALS OF ONCOLOGY», 2021, 32, pp. 839 - 853 [articolo]Open Access
Francesca Coppola, Margherita Mottola, Silvia Lo Monaco, Arrigo Cattabriga, Maria Adriana Cocozza, Jia Cheng Yuan, Caterina De Benedittis, Dajana Cuicchi, Alessandra Guido, Fabiola Lorena Rojas Llimpe, Antonietta D’Errico, Andrea Ardizzoni, Gilberto Poggioli, Lidia Strigari, Alessio Giuseppe Morganti, Franco Bazzoli, Luigi Ricciardiello, Rita Golfieri, Alessandro Bevilacqua, The Heterogeneity of Skewness in T2W-Based Radiomics Predicts the Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer, «DIAGNOSTICS», 2021, 11, Article number: 795, pp. 1 - 13 [articolo]Open Access
Raschi, Emanuel; Fusaroli, Michele; Ardizzoni, Andrea; Poluzzi, Elisabetta; De Ponti, Fabrizio, Thromboembolic Events with Cyclin-Dependent Kinase 4/6 Inhibitors in the FDA Adverse Event Reporting System, «CANCERS», 2021, 13, Article number: 1758, pp. 1 - 12 [articolo]Open Access
Tarricone R.; Listorti E.; Tozzi V.; Torbica A.; Banks H.; Ghislandi S.; Altini M.; Annicchiarico M.; Ardizzoni A.; Bordon P.; Bossi P.; Cascinu S.; Numico G.; Puglisi F.; Fasola G., Transformation of Cancer Care during and after the COVID Pandemic, a point of no return. The Experience of Italy, «JOURNAL OF CANCER POLICY», 2021, 29, Article number: 100297, pp. 1 - 5 [articolo]Open Access
Taronna G.; Leonetti A.; Gustavo Dall'Olio F.; Rizzo A.; Parisi C.; Buti S.; Bordi P.; Brocchi S.; Golfieri R.; Ardizzoni A.; Sverzellati N.; Tiseo M., Transient asymptomatic pulmonary opacities and interstitial lung disease in EGFR-mutated non-small cell lung cancer treated with osimertinib, «TUMORI», 2021, 00(0), pp. 1 - 8 [articolo]
Mollica V.; Brocchi S.; Dall'olio F.G.; Marcolin L.; Paccapelo A.; Santoni M.; Rizzo A.; Montironi R.; Golfieri R.; Massari F.; Ardizzoni A., Tumor growth rate decline despite progressive disease may predict improved nivolumab treatment outcome in mrcc: When recist is not enough, «CANCERS», 2021, 13, Article number: 3492, pp. 1 - 10 [articolo]Open Access
Morgensztern D.; Dols M.C.; Ponce Aix S.; Postmus P.E.; Bennouna J.; Fischer J.R.; Juan-Vidal O.; Stewart D.J.; Ardizzoni A.; Bhore R.; Wolfsteiner M.; Reck M.; Talbot D.; Govindan R.; Ong T.J., nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+), «FRONTIERS IN ONCOLOGY», 2021, 10, Article number: 569715, pp. 1 - 9 [articolo]Open Access
Massucci, Maria; Di Fabio, Francesca; Rojas Llimpe, Fabiola L; Ardizzoni, Andrea, A Case of Response to Immunotherapy in a Patient With MSI Metastatic Colorectal Cancer and Autoimmune Disease in Steroid Therapy, «JOURNAL OF IMMUNOTHERAPY», 2020, 43, pp. 153 - 155 [articolo]
Vitale G.; Lamberti G.; Comito F.; Di Nunno V.; Massari F.; Morelli M.C.; Ardizzoni A.; Gelsomino F., Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2020, 20, pp. 1047 - 1059 [articolo]
Gelsomino F.; Lamberti G.; Tiseo M.; Rocco D.; Pasello G.; Cecere F.L.; Chella A.; Grilli G.; Mandruzzato M.; Tognetto M.; Garassino M.C.; Macerelli M.; Novello S.; Roila F.; Colantonio I.; Grossi F.; Fiorentino M.; Ardizzoni A., Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial), «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, pp. 1 - 6 [articolo]Open Access
Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A., Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma, «CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY», 2020, 156, Article number: 103119, pp. 1 - 18 [articolo]
Dall'Olio F.G.; Abbati F.; Facchinetti F.; Massucci M.; Melotti B.; Squadrilli A.; Buti S.; Formica F.; Tiseo M.; Ardizzoni A., CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors, «THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY», 2020, 12, Article number: 1758835920952994, pp. 1 - 4 [articolo]Open Access
Felip E.; Ardizzoni A.; Ciuleanu T.; Cobo M.; Laktionov K.; Szilasi M.; Califano R.; Carcereny E.; Griffiths R.; Paz-Ares L.; Duchnowska R.; Garcia M.A.; Isla D.; Jassem J.; Appel W.; Milanowski J.; Van Meerbeeck J.P.; Wolf J.; Li A.; Acevedo A.; Popat S., CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations, «EUROPEAN JOURNAL OF CANCER», 2020, 127, pp. 160 - 172 [articolo]Open Access
Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A., Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience, «LUNG CANCER», 2020, 149, pp. 5 - 9 [articolo]
